BioCentury
ARTICLE | Clinical News

Progenitor cell gene therapy with the normal version of the p47phox gene data

December 11, 1995 8:00 AM UTC

SOMA and Baxter announced data from three of five patients in a Phase I trial, showing that two of the three had small numbers of granulocytes in the blood with fully restored function.

Patients with CGD lack granulocytes capable of producing oxidizing agents needed to kill ingested bacteria and fungi, leading to recurring infections. In about one-third of CGD patients, the disease is caused by a defect in the p47 gene. ...